The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: A randomized, double‐blind, placebo‐controlled, multicenter study
Identifieur interne : 000127 ( Main/Exploration ); précédent : 000126; suivant : 000128The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: A randomized, double‐blind, placebo‐controlled, multicenter study
Auteurs : Hasmet A. Hanagasi [Turquie] ; Hakan Gurvit [Turquie] ; P Nar Unsalan [Turquie] ; Hilal Horozoglu [Turquie] ; Nese Tuncer [Turquie] ; Aynur Feyzioglu [Turquie] ; Dilek Ince Gunal [Turquie] ; Gorsev G. Yener [Turquie] ; Raif Cakmur [Turquie] ; Huseyin A. Sahin [Turquie] ; Murat Emre [Turquie]Source :
- Movement Disorders [ 0885-3185 ] ; 2011-08-15.
English descriptors
Abstract
Cognitive impairment can occur at all stages of Parkinson's disease. Rasagiline is a selective monoamine oxidase type‐B inhibitor that enhances central dopaminergic transmission. Dopamine is thought to be involved in certain cognitive processes such as working memory. We assessed the effects of rasagiline on cognitive deficits in cognitively impaired, nondemented patients with Parkinson's disease. This was a randomized, double‐blind, placebo‐controlled prospective study. Patients with Parkinson's disease receiving stable dopaminergic treatment were assigned to receive rasagiline 1 mg/day or placebo for 3 months. Patients were eligible if they had impairment in 2 of 4 cognitive domains (attention, executive functions, memory, visuospatial functions) in the screening neuropsychological tests, yet did not fulfill criteria for Parkinson's disease dementia. Fifty‐five patients were randomized; 48 patients completed the study. Patients in the rasagiline group showed significant improvement in digit span–backward compared with the placebo group (P = .04), with trends favoring rasagiline in digit span total and digit‐ordering tests. Verbal fluency total score showed a significant difference in favor of rasagiline (P = .038), with trends favoring rasagiline in semantic fluency test and Stroop spontaneous corrections. The composite cognitive domain Z scores revealed a significant difference in favor of rasagiline compared with placebo in the attentional Z score (P < .005). There were no significant differences between the 2 groups in the other cognitive tests or cognitive domain Z scores. The monoamine oxidase type‐B inhibitor rasagiline may exert beneficial effects on certain aspects of attention and executive functions in nondemented patients with Parkinson's disease with cognitive impairment. © 2011 Movement Disorder Society
Url:
DOI: 10.1002/mds.23738
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: A randomized, double‐blind, placebo‐controlled, multicenter study</title><author><name sortKey="Hanagasi, Hasmet A" sort="Hanagasi, Hasmet A" uniqKey="Hanagasi H" first="Hasmet A." last="Hanagasi">Hasmet A. Hanagasi</name></author><author><name sortKey="Gurvit, Hakan" sort="Gurvit, Hakan" uniqKey="Gurvit H" first="Hakan" last="Gurvit">Hakan Gurvit</name></author><author><name sortKey="Unsalan, P Nar" sort="Unsalan, P Nar" uniqKey="Unsalan P" first="P Nar" last="Unsalan">P Nar Unsalan</name></author><author><name sortKey="Horozoglu, Hilal" sort="Horozoglu, Hilal" uniqKey="Horozoglu H" first="Hilal" last="Horozoglu">Hilal Horozoglu</name></author><author><name sortKey="Tuncer, Nese" sort="Tuncer, Nese" uniqKey="Tuncer N" first="Nese" last="Tuncer">Nese Tuncer</name></author><author><name sortKey="Feyzioglu, Aynur" sort="Feyzioglu, Aynur" uniqKey="Feyzioglu A" first="Aynur" last="Feyzioglu">Aynur Feyzioglu</name></author><author><name sortKey="Gunal, Dilek Ince" sort="Gunal, Dilek Ince" uniqKey="Gunal D" first="Dilek Ince" last="Gunal">Dilek Ince Gunal</name></author><author><name sortKey="Yener, Gorsev G" sort="Yener, Gorsev G" uniqKey="Yener G" first="Gorsev G." last="Yener">Gorsev G. Yener</name></author><author><name sortKey="Cakmur, Raif" sort="Cakmur, Raif" uniqKey="Cakmur R" first="Raif" last="Cakmur">Raif Cakmur</name></author><author><name sortKey="Sahin, Huseyin A" sort="Sahin, Huseyin A" uniqKey="Sahin H" first="Huseyin A." last="Sahin">Huseyin A. Sahin</name></author><author><name sortKey="Emre, Murat" sort="Emre, Murat" uniqKey="Emre M" first="Murat" last="Emre">Murat Emre</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:BC75E8D7F3F0CE5964F817BD46FCD38B83205583</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1002/mds.23738</idno><idno type="url">https://api.istex.fr/document/BC75E8D7F3F0CE5964F817BD46FCD38B83205583/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001688</idno><idno type="wicri:Area/Main/Curation">001452</idno><idno type="wicri:Area/Main/Exploration">000127</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: A randomized, double‐blind, placebo‐controlled, multicenter study</title><author><name sortKey="Hanagasi, Hasmet A" sort="Hanagasi, Hasmet A" uniqKey="Hanagasi H" first="Hasmet A." last="Hanagasi">Hasmet A. Hanagasi</name><affiliation wicri:level="1"><country xml:lang="fr">Turquie</country><wicri:regionArea>Istanbul University, Istanbul Faculty of Medicine, Department of Neurology, Istanbul</wicri:regionArea><wicri:noRegion>Istanbul</wicri:noRegion></affiliation></author><author><name sortKey="Gurvit, Hakan" sort="Gurvit, Hakan" uniqKey="Gurvit H" first="Hakan" last="Gurvit">Hakan Gurvit</name><affiliation wicri:level="1"><country xml:lang="fr">Turquie</country><wicri:regionArea>Istanbul University, Istanbul Faculty of Medicine, Department of Neurology, Istanbul</wicri:regionArea><wicri:noRegion>Istanbul</wicri:noRegion></affiliation></author><author><name sortKey="Unsalan, P Nar" sort="Unsalan, P Nar" uniqKey="Unsalan P" first="P Nar" last="Unsalan">P Nar Unsalan</name><affiliation wicri:level="1"><country xml:lang="fr">Turquie</country><wicri:regionArea>Istanbul University, Istanbul Faculty of Medicine, Department of Neurology, Istanbul</wicri:regionArea><wicri:noRegion>Istanbul</wicri:noRegion></affiliation></author><author><name sortKey="Horozoglu, Hilal" sort="Horozoglu, Hilal" uniqKey="Horozoglu H" first="Hilal" last="Horozoglu">Hilal Horozoglu</name><affiliation wicri:level="1"><country xml:lang="fr">Turquie</country><wicri:regionArea>Marmara University, Department of Neurology, Istanbul</wicri:regionArea><wicri:noRegion>Istanbul</wicri:noRegion></affiliation></author><author><name sortKey="Tuncer, Nese" sort="Tuncer, Nese" uniqKey="Tuncer N" first="Nese" last="Tuncer">Nese Tuncer</name><affiliation wicri:level="1"><country xml:lang="fr">Turquie</country><wicri:regionArea>Marmara University, Department of Neurology, Istanbul</wicri:regionArea><wicri:noRegion>Istanbul</wicri:noRegion></affiliation></author><author><name sortKey="Feyzioglu, Aynur" sort="Feyzioglu, Aynur" uniqKey="Feyzioglu A" first="Aynur" last="Feyzioglu">Aynur Feyzioglu</name><affiliation wicri:level="1"><country xml:lang="fr">Turquie</country><wicri:regionArea>Marmara University, Department of Neurology, Istanbul</wicri:regionArea><wicri:noRegion>Istanbul</wicri:noRegion></affiliation></author><author><name sortKey="Gunal, Dilek Ince" sort="Gunal, Dilek Ince" uniqKey="Gunal D" first="Dilek Ince" last="Gunal">Dilek Ince Gunal</name><affiliation wicri:level="1"><country xml:lang="fr">Turquie</country><wicri:regionArea>Marmara University, Department of Neurology, Istanbul</wicri:regionArea><wicri:noRegion>Istanbul</wicri:noRegion></affiliation></author><author><name sortKey="Yener, Gorsev G" sort="Yener, Gorsev G" uniqKey="Yener G" first="Gorsev G." last="Yener">Gorsev G. Yener</name><affiliation wicri:level="1"><country xml:lang="fr">Turquie</country><wicri:regionArea>Dokuz Eylul University, Department of Neurology and Neurosciences, Brain Dynamics Research Center, Izmir</wicri:regionArea><wicri:noRegion>Izmir</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Turquie</country><wicri:regionArea>Istanbul Kultur University, Brain Dynamics and Cognition Research Center, Istanbul</wicri:regionArea><wicri:noRegion>Istanbul</wicri:noRegion></affiliation></author><author><name sortKey="Cakmur, Raif" sort="Cakmur, Raif" uniqKey="Cakmur R" first="Raif" last="Cakmur">Raif Cakmur</name><affiliation wicri:level="1"><country xml:lang="fr">Turquie</country><wicri:regionArea>Dokuz Eylul University, Department of Neurology and Neurosciences, Brain Dynamics Research Center, Izmir</wicri:regionArea><wicri:noRegion>Izmir</wicri:noRegion></affiliation></author><author><name sortKey="Sahin, Huseyin A" sort="Sahin, Huseyin A" uniqKey="Sahin H" first="Huseyin A." last="Sahin">Huseyin A. Sahin</name><affiliation wicri:level="1"><country xml:lang="fr">Turquie</country><wicri:regionArea>Ondokuz Mayis University, Department of Neurology, Samsun</wicri:regionArea><wicri:noRegion>Samsun</wicri:noRegion></affiliation></author><author><name sortKey="Emre, Murat" sort="Emre, Murat" uniqKey="Emre M" first="Murat" last="Emre">Murat Emre</name><affiliation wicri:level="1"><country xml:lang="fr">Turquie</country><wicri:regionArea>Istanbul University, Istanbul Faculty of Medicine, Department of Neurology, Istanbul</wicri:regionArea><wicri:noRegion>Istanbul</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-08-15">2011-08-15</date><biblScope unit="volume">26</biblScope><biblScope unit="issue">10</biblScope><biblScope unit="page" from="1851">1851</biblScope><biblScope unit="page" to="1858">1858</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">BC75E8D7F3F0CE5964F817BD46FCD38B83205583</idno><idno type="DOI">10.1002/mds.23738</idno><idno type="ArticleID">MDS23738</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>attention</term><term>cognitive impairment</term><term>rasagiline</term><term>treatment</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Cognitive impairment can occur at all stages of Parkinson's disease. Rasagiline is a selective monoamine oxidase type‐B inhibitor that enhances central dopaminergic transmission. Dopamine is thought to be involved in certain cognitive processes such as working memory. We assessed the effects of rasagiline on cognitive deficits in cognitively impaired, nondemented patients with Parkinson's disease. This was a randomized, double‐blind, placebo‐controlled prospective study. Patients with Parkinson's disease receiving stable dopaminergic treatment were assigned to receive rasagiline 1 mg/day or placebo for 3 months. Patients were eligible if they had impairment in 2 of 4 cognitive domains (attention, executive functions, memory, visuospatial functions) in the screening neuropsychological tests, yet did not fulfill criteria for Parkinson's disease dementia. Fifty‐five patients were randomized; 48 patients completed the study. Patients in the rasagiline group showed significant improvement in digit span–backward compared with the placebo group (P = .04), with trends favoring rasagiline in digit span total and digit‐ordering tests. Verbal fluency total score showed a significant difference in favor of rasagiline (P = .038), with trends favoring rasagiline in semantic fluency test and Stroop spontaneous corrections. The composite cognitive domain Z scores revealed a significant difference in favor of rasagiline compared with placebo in the attentional Z score (P < .005). There were no significant differences between the 2 groups in the other cognitive tests or cognitive domain Z scores. The monoamine oxidase type‐B inhibitor rasagiline may exert beneficial effects on certain aspects of attention and executive functions in nondemented patients with Parkinson's disease with cognitive impairment. © 2011 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Turquie</li></country></list><tree><country name="Turquie"><noRegion><name sortKey="Hanagasi, Hasmet A" sort="Hanagasi, Hasmet A" uniqKey="Hanagasi H" first="Hasmet A." last="Hanagasi">Hasmet A. Hanagasi</name></noRegion><name sortKey="Cakmur, Raif" sort="Cakmur, Raif" uniqKey="Cakmur R" first="Raif" last="Cakmur">Raif Cakmur</name><name sortKey="Emre, Murat" sort="Emre, Murat" uniqKey="Emre M" first="Murat" last="Emre">Murat Emre</name><name sortKey="Feyzioglu, Aynur" sort="Feyzioglu, Aynur" uniqKey="Feyzioglu A" first="Aynur" last="Feyzioglu">Aynur Feyzioglu</name><name sortKey="Gunal, Dilek Ince" sort="Gunal, Dilek Ince" uniqKey="Gunal D" first="Dilek Ince" last="Gunal">Dilek Ince Gunal</name><name sortKey="Gurvit, Hakan" sort="Gurvit, Hakan" uniqKey="Gurvit H" first="Hakan" last="Gurvit">Hakan Gurvit</name><name sortKey="Horozoglu, Hilal" sort="Horozoglu, Hilal" uniqKey="Horozoglu H" first="Hilal" last="Horozoglu">Hilal Horozoglu</name><name sortKey="Sahin, Huseyin A" sort="Sahin, Huseyin A" uniqKey="Sahin H" first="Huseyin A." last="Sahin">Huseyin A. Sahin</name><name sortKey="Tuncer, Nese" sort="Tuncer, Nese" uniqKey="Tuncer N" first="Nese" last="Tuncer">Nese Tuncer</name><name sortKey="Unsalan, P Nar" sort="Unsalan, P Nar" uniqKey="Unsalan P" first="P Nar" last="Unsalan">P Nar Unsalan</name><name sortKey="Yener, Gorsev G" sort="Yener, Gorsev G" uniqKey="Yener G" first="Gorsev G." last="Yener">Gorsev G. Yener</name><name sortKey="Yener, Gorsev G" sort="Yener, Gorsev G" uniqKey="Yener G" first="Gorsev G." last="Yener">Gorsev G. Yener</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000127 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000127 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:BC75E8D7F3F0CE5964F817BD46FCD38B83205583
|texte= The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: A randomized, double‐blind, placebo‐controlled, multicenter study
}}
| This area was generated with Dilib version V0.6.23. |  |